Company intelligence / Profile preview

Juniper Pharmaceuticals, Inc.

Boston, Massachusetts, United Statescontractpharma.com ↗

Ownership: Private
Employees: ~65
Development stage: Commercial

Overview

Juniper had a commercially approved product, Crinone 8% (progesterone gel), marketed by Allergan in the US and Merck KGaA in over 90 countries. They were developing COL-1077, a 10% lidocaine bioadhesive gel for gynecological procedures, which was in Phase 2 trials[1][4].

Therapeutic areas: EndocrinologyUrologyWomen's Health
Modalities: Small moleculesdrug delivery technologies
Industry: Biotech

Drug pipeline

4 assets

progesterone gel

Commercial

Indications: Women's health

3 more assets in the full pipeline.

Request access →

Partnerships

Allergan (US marketing of Crinone)Merck KGaA (international marketing of Crinone)

Beyond the preview

Go deeper on Juniper Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juniper Pharmaceuticals, Inc..

Explore the full profile